Sobi - Swedish Orphan Biovitrum AB (publ) · 1 month ago
Sr. Director, Immunology Strategy
Waltham, MA, USA
Full-time
Hybrid
Director/Executive
$207K/yr - $260K/yr
10+ years expSobi is dedicated to developing innovative therapies for rare diseases and is seeking a Sr. Director of Immunology Strategy to enhance their immunology commercial strategy. This role involves driving sales effectiveness, managing strategic initiatives, and collaborating with cross-functional teams to ensure the success of immunology brands and upcoming launches.
BiotechnologyGeneticsMedicalPharmaceutical
Responsibilities
Support the development and execution of immunology commercial strategy, focusing on ensuring the right priorities and building the necessary capabilities to enable
Support our launch teams with strategic guidance and drive ad hoc, critical initiatives that enhance our launches in Immunology
Define Immunology portfolio priorities with Marketing, Sales, Medical, Access, and Finance
Manage and execute ad hoc projects that align with the strategic goals of the immunology franchise
Support opportunity assessments for new disease areas and other life cycle management initiatives, providing insights and recommendations
Work with Sales, Market Access, Commercial Insights & Operations, Marketing, and other cross-functional leads to develop and execute high priority initiatives
Provide strategic and operational support to the sales team, ensuring alignment with immunology objectives
Provide support and strategic input into how we track performance, opportunities, and the impact of activities
Support targeting and alignments for commercial field roles, ensuring effective deployment of resources
Manage Immunology Leadership Team (LT) meetings with agenda setting preparation of materials, facilitation of the meetings, and follow-up activities
In partnership with other leaders, manage key team meetings (e.g., quarterly Immunology Town Halls, annual POAs)
Foster clear communication and coordination among various field roles and cross-functional teams to maximize impact and minimize confusion
Play a key role in evolving the culture within the immunology franchise, fostering collaboration and innovation
Lead development approach to enhance our Sobi Immunology presence and attract talent
Support initiatives (field collateral and digital engagement) to enhance Sobi's perception and awareness in Immunology across professional associations, key customers, and in coordination with advocacy and policy partner
Lead or support cross-functional PMOs focused on launch preparation and other business transitions, as needed, to ensure seamless operations, change management and value creation
Qualification
Required
Bachelor's degree in a relevant field; advanced degree (MBA or medical) preferred
10+ years working with/in Biopharma with a mix of direct Biopharma and top-tier consulting experience
Mix of strategy (corporate/brand/portfolio) and operational experience with significant U.S. market exposure
Launch and lifecycle experience in specialty/rare disease settings
Excellent communication and leadership skills, with experience in cross-functional collaboration and leadership
Strong analytical skills with the ability to develop clear insights and recommendations
Ability to manage and prioritize multiple projects and initiatives simultaneously, with a focus on achieving strategic goals
Highly developed organizational agility and 'can do' approach
Experience working closely with executive management in various work situations
Proficiency with PowerPoint, Microsoft Excel, AI Chat (e.g., ChatGPT, Gemini) and other reporting and tracking tools (e.g. Veeva CRM and Tableau)
Ability to travel up to 30%
Benefits
Competitive 401(k) match
Tuition and wellness reimbursements
Comprehensive medical, dental, and vision package
Additional recognition awards
Company
Sobi - Swedish Orphan Biovitrum AB (publ)
Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases.
1001-5000 employees
Funding
Current Stage
Public CompanyTotal Funding
$825.99M2024-05-08Post Ipo Debt· $274.92M
2023-08-22Post Ipo Equity· $551.07M
2006-09-15IPO
Leadership Team
Guido Oelkers
Chief Executive Officer
Recent News
PR Newswire
2026-01-16
News Powered by Cision
2026-01-16
Company data provided by crunchbase